Ionis Pharmaceuticals
IONS
350 hedge funds and large institutions have $5.59B invested in Ionis Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 97 increasing their positions, 130 reducing their positions, and 51 closing their positions.
106% more call options, than puts
Call options by funds: $25.6M | Put options by funds: $12.4M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more capital invested
Capital invested by funds: $4.61B → $5.59B (+$977M)
1.18% more ownership
Funds ownership: 87.84% → 89.03% (+1.2%)
0% more funds holding
Funds holding: 350 → 350 (0)
0% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 51
25% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 130
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$67.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$33.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.5M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$20.3M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$432M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$41.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$32.7M |
| 4 |
State Street
Boston,
Massachusetts
|
-$18.6M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$15.5M |
IONS Hedge Fund Activity: Q3 2022 in Review
350 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2022, worth a combined $5.59B — up 21% from $4.61B a quarter earlier.
Fund positioning in IONS was balanced in Q3 2022: 51 funds opened new positions, 51 closed out, 97 added to existing stakes and 130 trimmed.
The largest buyer was BVF Inc, adding an estimated $67.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $432M.
- 350 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $5.59B of Ionis Pharmaceuticals stock for Q3 2022, up 21% quarter-over-quarter.
- 51 funds opened new Ionis Pharmaceuticals positions in Q3 2022 and 51 closed out, a net change of 0 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2022 was BVF Inc, an estimated $67.3M added.
- The largest Ionis Pharmaceuticals seller in Q3 2022 was T. Rowe Price Associates, an estimated $432M sold.
Based on aggregated 13F filings for Q3 2022.